Dual receptor antagonistic antigen-binding proteins and uses thereof
US-9453080-B2 · Sep 27, 2016 · US
Dual receptor antagonistic antigen-binding proteins and uses thereof
US10981999B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10981999-B2 |
| Application number | US-201916293254-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2019 |
| Priority date | Jun 11, 2012 |
| Publication date | Apr 20, 2021 |
| Grant date | Apr 20, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that requires stimulation of muscle growth.
First claim
Opening claim text (preview).
The invention claimed is: 1. An isolated nucleic acid encoding an antigen-binding protein comprising a first polypeptide comprising SEQ ID NO: 15 and a second polypeptide comprising SEQ ID NO: 16, wherein the antigen-binding protein specifically binds to SEQ ID NO: 2 and SEQ ID NO: 18. 2. An expression vector comprising the nucleic acid of claim 1 . 3. A host cell comprising the vector of claim 2 . 4. The host cell of claim 3 wherein the cell is a eukaryotic or prokaryotic cell. 5. The host cell of claim 4 wherein the eukaryotic cell is a mammalian cell. 6. A method of producing an antigen-binding protein, comprising culturing the host cell of claim 3 under suitable conditions such that the nucleic acid is expressed to produce the antigen-binding protein. 7. The method of claim 6 , further comprising recovering the antigen-binding protein from a culture of the host cell.
Assignees
Inventors
Classifications
Complementarity determining region [CDR] · CPC title
against immunoglobulins · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
from primates, e.g. man · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10981999B2 cover?
- This disclosure related to antagonistic dual receptor antigen-binding proteins, e.g. antibodies and methods of using the dual receptor antibodies for treatment of pathological diseases. The dual receptor antibodies may comprise an antibody to ActRII receptors and may be used to treat pathological condition. The pathological conditions can comprise muscle wasting diseases or any disease that req…
- Who is the assignee on this patent?
- Amgen Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).